PI
CSTL icon

PEAK6 Investments’s Castle Biosciences CSTL Stock Holding History

PEAK6 Investments’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2,875
Closed -$75K – 4569
2022
Q3 		$75K Buy
+2,875
New +$80.6K ﹤0.01% 4221
2021
Q1 		– Sell
-147
Closed -$10K – 4929
2020
Q4 		$10K Buy
+147
New +$7.97K ﹤0.01% 4393

Other funds holding CSTL

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.65B AUM 23.83% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

PEAK6 Investments's CSTL Position: Q4 2022 in Review

PEAK6 Investments sold out of Castle Biosciences (CSTL) in Q4 2022, closing a stake of 2,875 shares — an estimated $75K sold.

PEAK6 Investments first reported a position in CSTL in Q4 2020 and held it in 2 quarters. The position peaked at $75K in Q3 2022. 153 funds tracked by Wall St. Rank hold CSTL as of Q4 2022.

  • PEAK6 Investments reported no remaining Castle Biosciences position as of Q4 2022 after selling out during the quarter.
  • PEAK6 Investments sold 2,875 Castle Biosciences shares in Q4 2022, an estimated $75K.
  • PEAK6 Investments first reported a position in Castle Biosciences in Q4 2020 and held it in 2 quarters.
  • PEAK6 Investments's Castle Biosciences position peaked at $75K in Q3 2022.
  • 153 funds tracked by Wall St. Rank held Castle Biosciences as of Q4 2022.

Based on PEAK6 Investments's 13F filing for Q4 2022, filed 10 Feb 2023.